Nucleic Acid Pathogen Testing - Cigna
A nucleic acid test analyzes tiny amounts of DNA or RNA in a sample of blood, tissue or body fluid. Because the amount of genetic material is very small the test may include a step where the DNA or RNA of the microorganism is amplified, or increased. This type of nucleic acid pathogen test is known as a nucleic acid amplification test or NAAT.
Download Nucleic Acid Pathogen Testing - Cigna
Information
Domain:
Source:
Link to this page:
Documents from same domain
Molecular Diagnostic Testing for Hematology and Oncology ...
static.cigna.comGeneral Criteria for Somatic Mutation Genetic Testing ... initiate a related therapy and the therapy has been validated by the National Comprehensive Cancer Network™ (NCCN Guidelines™) as a category 1, 2A, or 2B recommendation for the ... Detection of circulating whole tumor cells for any other indication is considered experimental,
Bariatric Surgery and Procedures - Cigna
static.cigna.comThis Coverage Policy addresses bariatric surgery and procedures for the treatment of morbid obesity. Coverage Policy . Coverage for bariatric surgery or revision of a bariatric surgery procedure varies across plans and may be governed by state mandates. Refer to the customer’s benefit plan document for coverage details.
Anesthesia Services for Interventional Pain Management ...
static.cigna.comMonitored anesthesia care (MAC) is a service rendered by an anesthesia practitioner (i.e., anesthesiologist, certified registered nurse anesthetist CRNA]) who is not involved in the diagnostic or procedural service being performed. The ASA defines MAC as
REVENUE CODE LIST-CPT-HCPCS - Cigna
static.cigna.comREVENUE CODE LIST-CPT-HCPCS For Providers Effective March 15, 2020 . All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, includingCigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service
Minimally Invasive Spine Surgery Procedures and Trigger ...
static.cigna.comTrigger Point: Trigger point injection therapy involves the injection of anesthetic or corticosteroids into distinct, focal hyper-irritable spots (i.e., trigger points) located in a tight band of skeletal muscle. Myofascial pain syndrome is a chronic form of muscle pain centered near trigger points.
Diabetes Equipment and Supplies
static.cigna.com• hypoglycemic wristband alarm (e.g., Diabetes Sentry™) External Insulin Pumps . ANY of the following external insulin pumps * is considered medically necessary for the management of type 1 and type 2 diabetes mellitus: • an external insulin pump* (HCPCS code E0784) including a combined or integrated continuous
Welcome to Cigna Behavioral Health
static.cigna.comThe practitioner has thirty (30) days from the receipt of the suspension or termination letter to make a written request for reconsideration. Cigna Behavioral Health's Credentialing Committee Appeal Panel will review the appeal at its next monthly meeting and issue a written notification of the outcome to the practitioner.
Speech Therapy - Cigna
static.cigna.comspeech-language pathologist for a significant voice disorder associated with the laryngeal structures that are associated with anatomic abnormality, neurological condition, injury (e.g., vocal nodules or polyps, vocal cord paresis or paralysis, paradoxical vocal …
Transcranial Magnetic Stimulation
static.cigna.comTranscranial Magnetic Stimulation (TMS) for Depression . Transcranial magnetic stimulation (TMS) is a non-invasive neurostimulation technique that modulates cortical excitability. In repetitive TMS (rTMS), trains of several pulses are delivered through repeated stimulation over the same area with frequencies ranging from 1 to 20 Hz.
Orthotic Devices and Shoes - Cigna
static.cigna.comI. Cranial Orthosis Coding for Cranial Orthoses • A custom molded/fitted cranial orthotic device (HCPCS code S1040) is considered medically necessary for the treatment of synostotic plagiocephaly (i.e., craniosynostosis) following surgical correction when the benefit plan includes coverage for this indication.
Related documents
Interpretation of Nucleic Acid 260/280 Ratios
tools.thermofisher.comnucleic acid absorbance at 260 nm is generally on a plateau, the absorbance curve at 280 nm is quite steeply sloped. A slight shift in wavelength accuracy will have a large effect on 260/280 ratios. It is possible to see as much as a 0.4 difference in the 260/280 ratio when measuring the same nucleic acid sample on two
Gastrointestinal Pathogen Nucleic Acid Detection Panel ...
www.uhcprovider.comGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea Page 2 of 10 UnitedHealthcare Commercial Medical Policy Effective 03/01/2021 Proprietary Information of UnitedHealthcare.
Assessment of Nucleic Acid Purity - Yale School of Medicine
medicine.yale.edunucleic acid are often higher than the respective 260/280 values. Expected 260/230 values are commonly in the range of 2.0-2.2. Residual chemical contamination from nucleic acids extraction procedures may result an overestimation of the nucleic acid concentration and/or negatively influence downstream analysis.
Nucleic Acid - Thermo Fisher Scientific
tools.thermofisher.comFor nucleic acid quantification, a modification of the Beer-Lambert equation is used to calculate sample concentrations. Nucleic acid sample concentrations are based on the absorbance at 260 nm, the selected analysis constant and a baseline correction. The generally accepted extinction coefficients or constants for nucleic acids
Spectrophotometric Nucleic Acid Quantification
www.biotek.comLight absorbed by the nucleic acid in the sample correlates to the concentration of nucleic acid present. Both DNA and RNA absorb light at 260 nm, therefore this is a measurement of total nucleic acid. Nucleic acid samples are also typically measured at 280 nm, which is the absorbance peak for protein. The ratio
DAPI Nucleic Acid Stain - Thermo Fisher Scientific
assets.thermofisher.comDAPI Nucleic Acid Stain | 4 2.3 Tap the tube to resuspend the pellet in the residual liquid and add 1 mL of PBS at room temperature. 2.4 Transfer the full volume of resuspended cells to 4 mL of absolute ethanol at –20°C by pipetting the cell suspension slowly into the ethanol while vortexing at top speed. Leave the cells in ethanol at –20°C for 5–15 minutes.